Zealand Pharma's Survodutide faces market pressure despite strong efficacy data due to gastrointestinal side effects

Shares of Zealand Pharma dropped after new late-stage trial results for its experimental obesity drug, survodutide, highlighted tolerability issues despite promising efficacy in weight loss and blood sugar control. Zealand Pharma shares fell sharply on Thursday after new late-stage data…













